Opstapelen schreef op 23 april 2021 08:09:
R&D update, nice
novacyt.com/wp-content/uploads/2021/0...Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an
update on the progress of its near-term COVID-19 research and development (R&D)
programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2
continues to mutate around the world. Novacyt also provides an update on its UK
operations.
R&D highlights
• Expansion of PathFlow® lateral flow test (LFT) portfolio with COVID-19 tests
o Launch of LFT to detect SARS-CoV-2 IgG antibodies
o Development of LFT to detect and differentiate between SARS-CoV-2 IgG
antibodies, launch expected Q3 2021
o Development of LFT to detect antigens for SARS-CoV-2, launch expected by
end of Q2 2021
• Expansion of genesig® COVID-19 polymerase chain reaction (PCR) portfolio
o Launch of CE Mark three-gene target PCR test
• Expansion of PROmate™ COVID-19 PCR portfolio for workflow efficiency in a nearto-patient setting
o Development of two-gene target test, launch expected May 2021
o Launch of test to identify a key mutation, E484K, found in all current
variants of concern (VOC)
• Expansion of SNPsig® COVID-19 PCR genotyping portfolio to detect SARS-CoV-2
variants
o Launch of CE Mark VariPLEX™ assay panel to detect multiple variants
o Development of test to detect a variant originally identified in India, launch
expected week commencing 26 April 2021
UK operational highlights
• Expansion of UK commercial infrastructure
• Inclusion in Public Health England (PHE) National Framework Agreement
Graham Mullis, Chief Executive Officer of Novacyt, commented:
“The continued development and expansion of our COVID-19 portfolio demonstrates
Novacyt’s ability to match the rapid evolution of SARS-CoV-2 with real-time bioinformatics
surveillance and accelerated product development. We remain committed to identifying
patient needs and overcoming healthcare challenges today and in the years ahead as we
continue to strengthen our position as a leading innovator in diagnostic testing.
“We are also pleased to be included in the PHE national framework, which allows PHE and
NHS hospitals to purchase our accredited products without the need for direct contract
awards. We look forward to the opportunity to expand our support of diagnostic testing in
the UK through our established infrastructure and building a long-term future in this
important market, as well as in international markets as we continue to invest in our direct
commercial operations.”